References
- Knights D, Lassen KG, Xavier RJ. Advances in inflammatory bowel disease pathogenesis: linking host genetics and the microbiome. Gut 2013;62(10):1505-10
- Canavese G, Bassotti G, Astegiano M, et al. Inflammatory bowel disease: a proposal to facilitate the achievement of an unequivocal diagnosis. World J Gastroenterol 2013;19(3):426-8
- Nappo A, Iacoviello L, Fraterman A, et al. High-sensitivity C-reactive protein is a predictive factor of adiposity in children: results of the identification and prevention of dietary- and lifestyle-induced health effects in children and infants (IDEFICS) study. J Am Heart Assoc 2013;2(3)): e000101
- Waugh N, Cummins E, Royle P, et al. Faecal calprotectin testing for differentiating amongst inflammatory and non-inflammatory bowel diseases: systematic review and economic evaluation. Health Technol Asses 2013;17(55)):xv-xix. 1-211
- Probert CSJ. Role of faecal gas analysis for the diagnosis of IBD. Biochem Soc Trans 2011;39:1079-80
- Probert CSJ, Ahmed I, Khalid T, et al. Volatile organic compounds as diagnostic biomarkers in gastrointestinal and liver diseases. J Gastrointest Liver Dis 2009;18(3):337-43
- Arasaradnam RP, Covington JA, Harmston C, Nwokolo CU. Review article: next generation diagnostic modalities in gastroenterology – gas phase volatile compound biomarker detection. Aliment Pharmacol Ther 2014;39(8):780-9
- Ratcliffe NM, de Lacy Costello B, Shepherd S. The use of MS for the investigation of irritable bowel syndrome and inflammatory bowel disease. Clin Lab Int Magazine 2013;37:18-20
- Altomare DF, Di Lena M, Porcelli F, et al. Exhaled volatile organic compounds identify patients with colorectal cancer. Br J Surg 2013;100(1):144-50
- Khalid T, White P, De Lacy Costello B, et al. A pilot study combining a GC-sensor device with a statistical model for the identification of bladder cancer from urine headspace. PloS One 2013;8(7)): e69602
- de Lacy Costello B, Ratcliffe N M. Volatile organic compounds (VOCs) found in urine and stool. In: Volatile biomarkers: non-invasive diagnosis in physiology and medicine 1st edn. Amann A, Smith D, Editors Amsterdam: Elsevier; 2013. pp 405-62
- Arasaradnam RP, Ouaret N, Thomas MG, et al. A novel tool for noninvasive diagnosis and tracking of patients with inflammatory bowel disease. Inflamm Bowel Dis 2013;19(5):999-1003
- Patel N, Cikach F, Eng K, et al. Metabolomic analysis of exhaled breath to identify volatile organic compounds (VOCs) in children with inflammatory bowel disease. Gastroenterology 2013;144(5):S710-0
- Jayasena H, Khalid T, Probert CS. PTU-076 Diagnostic potential of volatile organic compounds as faecal biomarkers in inflammatory bowel disease. Gut 2013;62(Suppl 1)):A75-6
- Walton C, Fowler DP, Turner C, et al. Analysis of volatile organic compounds of bacterial origin in chronic gastrointestinal diseases. Inflamm Bowel Dis 2013;19(10):2069-78
- Garner CE, Smith S, Costello BD, et al. Volatile organic compounds from feces and their potential for diagnosis of gastrointestinal disease. FASEB J 2007;21(8):1675-88
- Ahmed I, Greenwood R, Costello BD, et al. An investigation of fecal volatile organic metabolites in irritable bowel syndrome. PloS One 2013;8(3)): e58204
- Kinross JM, Darzi AW, Nicholson JK. Gut microbiome-host interactions in health and disease. Genome Med 2011;3(3):14
- Ahmed I, Smith S, Probert CS. Volatile organic compounds as diagnostic faecal biomarkers in inflammatory bowel disease method development. Gut 2009;58:A63-3
- Reade S, Mayor A, Aggio R, et al. Optimisation of sample preparation for direct SPME–GC–MS analysis of murine and human faecal volatile organic compounds for metabolomic studies. J Anal Bioanal Tech 2014;5(2)
- Shepherd SF, McGuire ND, de Lacy Costello BP, et al. The use of a gas chromatograph coupled to a metal oxide sensor for rapid assessment of stool samples from irritable bowel syndrome and inflammatory bowel disease patients. J Breath Res 2014;8(2):026001